Laboratory identification of hereditary risk of breast and ovarian cancer

Current Opinion in Biotechnology

Volumn 10, Issue 3, 1999, Pages 289-294

  Frank, Thomas S ^a  

^a Myriad Genetic Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

BREAST CANCER; FAMILIAL CANCER; FEMALE; GENE MUTATION; HUMAN; LABORATORY DIAGNOSIS; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL; REVIEW;

EID: 0033152399     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0958-1669(99)80051-2     Document Type: Review

References (55)

1. Shih C, Weinberg RA: Isolation of a transforming sequence from a human bladder carcinoma cell line. Cell 1982, 29:161 -169.
2. Baringa M: From bench top to bedside. Science 1997, 278:1036-1039.
3. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Salmon DJ: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998, 16:2659-2671.
4. Ponder B: Genetic testing for cancer risk. Science 1997, 278:1050-1058.
5. Statement of the American Society of Clinical Oncology: Genetic testing for cancer susceptibility. J Clin Oncol 1996, 14:1730-1736.
6. Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Hvey B, King MC: Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990, 250:1684-1689.
7. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennet LM, Ding W et al.: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994, 266:66-71.
8. Tavtigian SV, Simard J, Rommens J, Couch F, Shatttuck-Eidens D, Neuhausen S, Merajver S, Thorlacius S, Offit K, Stoppa-Lyonnet D et al.: The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 1996, 12:333-337.
9. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G: Identification of the breast cancer susceptibility gene BRCA2. Nature 1995, 378:789-792.
10. Ford D, Easton DF, Stratton M, Narod S, Goldgor D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J et al.: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998, 62:676-689.
11. Narod SA, Risch H, Moslehi R, Dorum A, Neuhausen S, Olsson H, Provencher D, Radice P, Evans G, Bishop S et al.: Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med 1998, 339:424-428. This study observed that the risk of ovarian cancer was lower in women with mutations in BRCA1 and BRCA2 who had used oral contraceptives compared with those who did not.
12. Easton DF, Bishop DT, Ford D, Crockford GP, Breast cancer linkage consortium: Genetic linkage analysis in familial breast and ovarian cancer: Results from 214 families. Am J Hum Genet 1993, 52:678-701.
13. Frank TS, Manley SA, Olopade OI, Cummings S, Garber JE, Bernhardt B, Antman K, Russo D, Wood ME, Mullineau L et al.: Sequence analysis of BRCA1 and BRCA2: Correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 1998,16:2417-2425. This is the first study that correlated specific aspects of a family history with mutations in the BRCA1 and BRCA2 genes found by laboratory analysis.
14. Rajan JV, Wang M, Marquis ST, Chodosh LA: Brca2 is coordinately regulated with Brca1 during proliferation and differentiation in mammary epithelial cells. Proc Natl Acad Sci USA 1996, 93:13078-13083.
15. Chen J, Silver DP, Walpita D, Cantor SB, Gazdar AF, Tomlinson G, Couch FJ, Weber BL, Ashley T, Livingston DM, Scully R: Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Mol Cell 1998, 2:317-328.
16. Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feutenn J, Ashley T, Livingston DM: Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 1997, 88:265-275.
17. Scully R, Anderson SF, Chao DM, Wei W, Ye L, Young RA, Livingston DM, Parvin JD: BRCA1 is a component of the RNA polymerase II holoenzyme. Proc Natl Acad Sci USA 1997, 94:5605-5610.
18. Anderson SF, Schlegel BP, Nakajima T, Wolpin ES, Parvin JD: BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase A. Nat Genet 1998, 19:254-256.
19. Ouchi T, Monteiro ANA, August A, Aaronson SA, Hanafusa H: BRCA1 regulates p53-dependent gene expression. Proc Natl Acad Sci USA 1998, 95:2302-2306.
20. Hakem R, de la Pompa JL, Sirard C, Mo R, Woo M, Hakem A, Wakeham A, Potter J, Reitmair A, Biliia F et al.: The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. Cell 1996, 85:1009-1023.
21. Sharan SK, Morimatsu M, Albrecht U, Lim DS, Regel E, Dinh C, Sands A, Eichele G, Hasty P, Bradley A: Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 1997, 386:804-810.
22. Connor F, Bertwistle D, Mee PJ, Ross GM, SWift S, Grigorieva E, Tybulewicz VL, Ashworth A: Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutations. Nat Genet 1997, 17:423-430.
23. Gowen LC, Avrutskaya AV, Latour AM, Koller BH, Leadon SA: BRCA1 required for transcription-coupled repair of oxidative DNA damage. Science 1998, 281:1009-1012.
24. Abbott DW, Freeman ML, Holt JT: Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells. J Natl Cancer Inst 1998, 90:978-985.
25. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE, Breast cancer linkage consortium: Risks of cancer in BRCA1-mutation carriers. Lancet 1994, 343:692-695.
26. Whittemore AS, Gong G, Itnyre J: Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: Results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet 1997, 60:496-504.
27. Struewing JP, Hartge P, Wacholder S Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA: The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997, 336:1401-1408.
28. Couch FJ, DeShano ML, Blackwood MA, Calzone K, Stopfer J, Compeau L, Garguly A, Rebbeck T, Weber BL: BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 1997, 336:1409-1415.
29. Verhoog LC, Brekelmans CTM, Seynaeve C, van den Bosch LM, Dahmen G, van Geel AN, Tilanus-Linthorst MM, Bartels CC, Wagner A, van den Ouweland A et al.: Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 1998, 351:316-321.
30. Robson M, Gilewski T, Haas B, Levin D, Borgen P, Rajan P, Hirschaut Y, Pressman P, Rosen PP, Lesser ML et al.: BRCA-associated breast cancer in young women. J Clin Oncol 1998, 16:1642-1649.
31. Jóhannsson OT, Ranstam J, Borg A, Olsson H: Survival of BRCA1 breast and ovarian cancer patients: A population-based study from southern Sweden. J Clin Oncol 1998, 16:397-404.
32. Easton DF, Ford D, Bishop DT, Breast cancer linkage consortium: Breast and ovarian cancer incidence in BRCA1 -mutation carriers. Am J Hum Genet 1995, 56:265-271.
33. Tonin P, Weber B, Offit K, Couch F, Rebbeck TR, Neuhausen S, Godwin AK, Daly M, Wagner-Costalos J, Berman D: Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med 1996, 2:1179-1183.
34. Peelen T, van Vliet M, Petrij-Bosch A, Mieremet R, Szabo C, van den Ouweland AM, Hogervorst F, Brohet R, Lightenberg MJ, Tengels E et al.: A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families. Am J Hum Genet 1997, 60:1041-1049.
35. Thorlacius S, Olafdottir G, Tryggvadottir L, Neuhausen S, Jonasson JG, Tavtigian SV, Tulinius H, Ogmundsdottir HM, Eyfjörd JE: A single BRCA2 mutation in male and female breast cancer cases and breast cancer families. Nat Genet 1996, 13:117-119.
36. Breast Cancer Information Core (BIC) on World Wide Web URL: http://www.nhgri.nih.gov/Intramural_research/Lab_transfer/BIC
37. FitzGerald MG, MacDonald DJ, Krainer M, Hoover I, O'Neil E, Unsal H, Silva-Arrieto S, Finkelstein DM, Beer-Romero P, Englert C et al.: Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med 1996, 334:143-149.
38. Abeliovich D, Kaduri L, Lerer I, Weinberg N, Amir G, Sagi M, Zlotogora J, Heching N, Peretz T et al.: The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 1997, 60:505-514.
39. Beller U, Halle D, Catane R, Kaufman B, Hornreich G, Levy-Lahad E: High frequency of BRCA1 and BRCA2 germline mutations in Ashkenazi Jewish ovarian cancer patients, regardless of family history. Gynecol Oncol 1997, 67:123-126.
40. Robson ME, Offit K: New BRCA2 mutation in an Ashkenazi Jewish family with breast and ovarian cancer. Lancet 1997, 350:117-118.
41. Petrij-Bosch A, Peelen T, van Vliet M, van Eijk R, Olmer R, Drüsedau M, Hagervorst FB, Hageman S, Arts PJ, Lightenberg MJ et al.: BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet 1997, 17:341-345.
42. Puget N, Torchard D, Serova-Sinilnikova OM, Lynch HT, Feunteun J, Lenoir GM, Mazayer S: A 1-kb Alu-mediated germ-line deletion removing BRCA1 exon 17. Cancer Res 1997, 57:828-831.
43. Roa BB, Boyd AA, Volcik K, Richards CS: Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996, 14:185-187.
44. Thorlacius S, Struewing JP, Hartge P, Olafsdottir GH, Sigvaldason H, Truggvadottir L, Wacholder S, Tulinius H, Eyfjörd JE: Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet 1998, 352:1337-1339.
45. Gayther SA, Mangion J, Russell P, Seal S, Barfoot R, Ponder BA, Stratton MR, Easton D: Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet 1997, 15:103-105.
46. Phelan CM, Rebbeck TR, Weber BL, Devilee P, Rutteledge MH, Lynch HT, Lenoir GM, Stratton MR, Easton DF, Ponder BA et al.: Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nat Genet 1996, 12:309-311.
47. Jordanova A, Kalaydjieva L, Savov A, Claustres M, Schwarz M, Eslivill X, Angelicheva D, Haworth A, Casals T, Kremensky I: SSCP analysis: A blind sensitivity trial. Hum Mutal 1997, 10:65-70.
48. Ganguly A, Rock MJ, Prockop DJ: Conformation-sensitive gel electrophoresis for rapid detection of single-base differences in double-stranded PCR products and DNA fragments: Evidence for solvent-induced bends in DNA heteroduplexes. Proc Natl Acad Sci USA 1993, 90:10325-10329.
49. Garrett CT, Ferreira-Centeno A, Nasim S: Molecular diagnostics: Issues of utilization, regulation, and organization. Clin Chim Acta 1993, 217:85-103.
50. Burke W, Daly M, Garber J, Botkin J, Kahn MJ, Lynch P, McTiernan A, Offit K, Perlman J, Petersen G et al.: Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer genetics studies consortium. JAMA 1997, 277:997-1003.
51. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J et al.: Tamoxifen for prevention of breast cancer: Report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 1998, 90:1371-1388. This large multicenter trial demonstrated that tamoxifen reduces the likelihood of developing breast cancer for women at an increased risk of the disease.
52. Hartmann LC, Schaid DJ, Woods JE, Crotty TP, Myers JL, Arnold PG, Petty PM, Sellers TA, Johnson JL, McDonnell et al.: Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. New Engl J Med 1999, 340:77-84.
53. Lerman C, Narod S, Schulman K, Hughes C, Gomez-Caminero A, Bonney G, Gold K, Trock B, Main D, Lynch J et al.: BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. JAMA 1996, 275:1885-1892.
54. NIH Consensus Development Panel on Ovarian Cancer: Ovarian cancer. Screening, treatment and follow-up. JAMA 1995, 273:491-497.
55. Rubin SC, Benjamin I, Behbakht K, Takahashi H, Morgan MA, Livolsi VA, Berchuck A, Muto MG, Garber JE, Weber BL et al.: Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. New Engl J Med 1996, 335:1413-1416.